Cardiovascular disease
-
ChecklistImplementing the ADA and EASD 2018 consensus report: management of hyperglycaemia in type 2 diabetes
Information intended for healthcare professionals only. This checklist has been commissioned and funded by Boehringer Ingelheim Limited and Lilly Diabetes Alliance and developed in partnership with Guidelines in Practice . Please see the bottom of the page for full disclaimer. View prescribing information If the PDF does not ...
-
Formulary decision guide
Jardiance® (empagliflozin) film-coated tablets
This formulary decision guide was initiated, funded, and reviewed by Boehringer Ingelheim Limited and Lilly Diabetes Alliance. The format was developed by Guidelines in Practice. View prescribing information Key points on this medicine Jardiance: is a once-daily SGLT2 inhibitor that improves ...
-
Test and reflect
SIGN guideline on pharmacological management of type 2 diabetes
This CPD activity consists of 5 multiple-choice questions (MCQs) designed to test your knowledge on SIGN guideline recommendations on managing type 2 diabetes—you will then be prompted to reflect on your learning.
-
Implementing guidelines
Cardiac rehabilitation should be individualised to meet patient needs
Dr Alan Begg explores updated SIGN recommendations on cardiac rehabilitation and strategies that encourage patient engagement in lifestyle risk factor management, psychosocial wellbeing, and behaviour change.
-
Implementing guidelines
Estimating cardiovascular risk is key to preventing disease
Dr Alan Begg summarises new SIGN guidance and explains why lifestyle change is an essential aspect of cardiovascular risk reduction
-
Top tips
Top tips: venous thromboembolism
Dr Alan Begg discusses the diagnosis, assessment, and management of thromboembolic disease in primary care
-
News
SIGN releases updated guidance on cardiovascular disease
The Scottish Intercollegiate Guidelines Network (SIGN) has published SIGN 149 Risk estimation and the prevention of cardiovascular disease and SIGN 150 Cardiac rehabilitation.
-
NICE quality standard article
Primary care needs a strategy to help identify CVD risk
Dr Ivan Benett shows how NICE has prioritised guidance on cardiovascular risk assessment and lipid modification into a quality standard to improve patient outcomes and experience
-
Personal view
Should everyone with a 10% risk of CVD take a statin?
Dr Terry McCormack revisits recent controversies about NICE guidance on statins and offers patient scenarios illustrating his own approach in clinical practice
-
Implementing guidelines
JBS3 guideline focuses on both short-term and lifetime risk of CVD
Professor John Deanfield explains how the JBS3 approach to CVD risk reduction encompasses the whole population rather than just those individuals at high short-term risk
